Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2869123,total plasma clearance,"Apomorphine showed a high total plasma clearance (165-207 ml min-1 kg-1) and, despite a relatively large volume of distribution (3.4-4.1 litre kg-1), a biological half-life of about 14 min was obtained irrespective of route of administration.",Concentration-response relations for apomorphine effects on heart rate in conscious rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869123/),[ml] / [kg·min],165-207,11969,DB00714,Apomorphine
,2869123,volume of distribution,"Apomorphine showed a high total plasma clearance (165-207 ml min-1 kg-1) and, despite a relatively large volume of distribution (3.4-4.1 litre kg-1), a biological half-life of about 14 min was obtained irrespective of route of administration.",Concentration-response relations for apomorphine effects on heart rate in conscious rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869123/),[l] / [kg],3.4-4.1,11970,DB00714,Apomorphine
,2869123,biological half-life,"Apomorphine showed a high total plasma clearance (165-207 ml min-1 kg-1) and, despite a relatively large volume of distribution (3.4-4.1 litre kg-1), a biological half-life of about 14 min was obtained irrespective of route of administration.",Concentration-response relations for apomorphine effects on heart rate in conscious rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869123/),min,14,11971,DB00714,Apomorphine
,7565822,bioavailability,"The mean bioavailability varied between 14.7% and 40.2%, which was the bioavailability until the end of clinical benefit.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),%,14.7,13684,DB00714,Apomorphine
,7565822,bioavailability,"The mean bioavailability varied between 14.7% and 40.2%, which was the bioavailability until the end of clinical benefit.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),%,40.2,13685,DB00714,Apomorphine
,7565822,Cmax,"Also, despite the differences in dose, the values of the Cmax were similar, with average values of 12.7-25.6 ng/ml.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),[ng] / [ml],12.7-25.6,13686,DB00714,Apomorphine
,7565822,Tmax,"Wide differences in Tmax were observed, with values varying between 16 min for the enema and 127.5 min for the Witepsol-H15 100-mg suppository.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,16,13687,DB00714,Apomorphine
,7565822,Tmax,"Wide differences in Tmax were observed, with values varying between 16 min for the enema and 127.5 min for the Witepsol-H15 100-mg suppository.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,127.5,13688,DB00714,Apomorphine
,7565822,onset time,"Onset of effect was similar for each of the preparations, with an average onset time of 14-28 min.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,14-28,13689,DB00714,Apomorphine
,7565822,duration of effect,The duration of effect after administration of the Witepsol-H15 100-mg suppository was 156 +/- 43 min versus 50 +/- 13 min after rectal administration of the apomorphine solution.,Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,156,13690,DB00714,Apomorphine
,7565822,duration of effect,The duration of effect after administration of the Witepsol-H15 100-mg suppository was 156 +/- 43 min versus 50 +/- 13 min after rectal administration of the apomorphine solution.,Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,50,13691,DB00714,Apomorphine
,8798925,flow-rate,"The HPLC assay comprised a 25 cm-long Techopak C18 column and a mobile phase of (0.25 M sodium dihydrogen phosphate plus 0.25% heptane sulphonic acid, to pH 3.3 with orthophosphoric acid) containing 30% (v/v) methanol and 0.003% (w/v) EDTA, run at a flow-rate of 1.5 ml/min.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[ml] / [min],1.5,23681,DB00714,Apomorphine
,8798925,initial half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,8.2,23682,DB00714,Apomorphine
,8798925,initial half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,46.6,23683,DB00714,Apomorphine
,8798925,elimination half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,76.4,23684,DB00714,Apomorphine
,8798925,elimination half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,166.5,23685,DB00714,Apomorphine
,8798925,area under the plasma concentration-time curve (AUC),"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[h·ng] / [ml],236,23686,DB00714,Apomorphine
,8798925,area under the plasma concentration-time curve (AUC),"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[h·ng] / [ml],405,23687,DB00714,Apomorphine
,26536022,half-life,"It was quickly eliminated with a half-life of 0.520 to 0.793 hour, suggesting no accumulation during multiple-dose phase.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),h,0.520 to 0.793,27119,DB00714,Apomorphine
,26536022,Cmax,The Cmax of apomorphine at effective dose was presumed to be approximately 20 ng/mL.,A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27120,DB00714,Apomorphine
,26536022,effective blood concentration,"Two-hour interval injections did not cause reduced responses, and effective blood concentration was presumed to be approximately 20 ng/mL similar, to the previous study conducted at North America.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27121,DB00714,Apomorphine
,1922125,relative bioavailability,The relative bioavailability of SL apomorphine ranged from 10 to 22% of a parenteral apomorphine dose.,Absorption of apomorphine by various routes in parkinsonism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),%,10 to 22,35334,DB00714,Apomorphine
less,1922125,bioavailable,"Oral apomorphine was less than 4% bioavailable, and the transdermal dose did not produce detectable plasma levels.",Absorption of apomorphine by various routes in parkinsonism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),%,4,35335,DB00714,Apomorphine
,1922125,latency to effect,"Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min.",Absorption of apomorphine by various routes in parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),min,20-40,35336,DB00714,Apomorphine
,1922125,duration of effect,"Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min.",Absorption of apomorphine by various routes in parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),min,15-100,35337,DB00714,Apomorphine
,9617506,clearance,The mean clearance of apomorphine was 4.5 L/min (2.2 to 6.6 L/min).,Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617506/),[l] / [min],4.5,36245,DB00714,Apomorphine
,9617506,minimal effective concentration (MEC),Clinical efficacy occurred at a mean minimal effective concentration (MEC) of 4.7 ng/mL (range 1.4 to 10.7 ng/mL).,Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617506/),[ng] / [ml],4.7,36246,DB00714,Apomorphine
,9617506,minimal toxic concentration,The mean minimal toxic concentration was 16.7 ng/mL (8.5 to 24.5 ng/mL) and was significantly different from the mean MEC.,Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617506/),[ng] / [ml],16.7,36247,DB00714,Apomorphine
,17069247,LOD,The linear range was 0.4-40 ng/mL with an LOD of 0.2 ng/mL for apomorphine in plasma.,Determination of apomorphine in canine plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17069247/),[ng] / [ml],0.2,38703,DB00714,Apomorphine
>,17069247,Extraction recoveries,Extraction recoveries were > 80%.,Determination of apomorphine in canine plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17069247/),%,80,38704,DB00714,Apomorphine
,9617507,clearance,"The values of relevant pharmacokinetic parameters were as follows: clearance 40 +/- 15 ml.min-1.kg-1, volume of distribution at steady state 1.6 +/- 0.5 l.kg-1, and terminal half-life 41 +/- 13 min.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),[ml] / [kg·min],40,46396,DB00714,Apomorphine
,9617507,volume of distribution at steady state,"The values of relevant pharmacokinetic parameters were as follows: clearance 40 +/- 15 ml.min-1.kg-1, volume of distribution at steady state 1.6 +/- 0.5 l.kg-1, and terminal half-life 41 +/- 13 min.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),[l] / [kg],1.6,46397,DB00714,Apomorphine
,9617507,terminal half-life,"The values of relevant pharmacokinetic parameters were as follows: clearance 40 +/- 15 ml.min-1.kg-1, volume of distribution at steady state 1.6 +/- 0.5 l.kg-1, and terminal half-life 41 +/- 13 min.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),min,41,46398,DB00714,Apomorphine
less,9617507,total excretion,"The total excretion of unconjugated S-apomorphine, apocodeine, and isoapocodeine was less than 0.1% of the administered dose.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,0.1,46399,DB00714,Apomorphine
,9617507,total excretion,"The total excretion of unchanged apomorphine, apomorphine sulfate, and apomorphine glucuronide amounted to 0.3 +/- 0.4%, 3.8 +/- 1% and 6.0 +/- 2.2% of the administered dose, respectively.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,0.3,46400,DB00714,Apomorphine
,9617507,total excretion,"The total excretion of unchanged apomorphine, apomorphine sulfate, and apomorphine glucuronide amounted to 0.3 +/- 0.4%, 3.8 +/- 1% and 6.0 +/- 2.2% of the administered dose, respectively.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,3.8,46401,DB00714,Apomorphine
,9617507,total excretion,"The total excretion of unchanged apomorphine, apomorphine sulfate, and apomorphine glucuronide amounted to 0.3 +/- 0.4%, 3.8 +/- 1% and 6.0 +/- 2.2% of the administered dose, respectively.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,6.0,46402,DB00714,Apomorphine
,16285020,quantification limits,The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine.,"Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16285020/),[ng] / [ml],1,55944,DB00714,Apomorphine
,16285020,quantification limits,The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine.,"Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16285020/),[ng] / [ml],25,55945,DB00714,Apomorphine
,16485914,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses.,Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485914/),h,1.5,61864,DB00714,Apomorphine
,7588990,absorption half life,"Apomorphine is rapidly absorbed when administered intranasally or subcutaneously with an absorption half life of 8.6 min and 5.8 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,8.6,68118,DB00714,Apomorphine
,7588990,absorption half life,"Apomorphine is rapidly absorbed when administered intranasally or subcutaneously with an absorption half life of 8.6 min and 5.8 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,5.8,68119,DB00714,Apomorphine
,7588990,tmax,"The tmax was 23 min for intranasal route and 18 min for the subcutaneous route while the lag times were 2.8 min and 3.9 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,23,68120,DB00714,Apomorphine
,7588990,tmax,"The tmax was 23 min for intranasal route and 18 min for the subcutaneous route while the lag times were 2.8 min and 3.9 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,18,68121,DB00714,Apomorphine
,7588990,lag times,"The tmax was 23 min for intranasal route and 18 min for the subcutaneous route while the lag times were 2.8 min and 3.9 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,2.8,68122,DB00714,Apomorphine
,7588990,lag times,"The tmax was 23 min for intranasal route and 18 min for the subcutaneous route while the lag times were 2.8 min and 3.9 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,3.9,68123,DB00714,Apomorphine
,7588990,bioavailability,The bioavailability of intranasal apomorphine compared to the subcutaneous route amounted to 45%.,Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),%,45,68124,DB00714,Apomorphine
,7588990,elimination half life,"After intranasal and subcutaneous administrations, the elimination half life of apomorphine amounted to 31 min and 27 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,31,68125,DB00714,Apomorphine
,7588990,elimination half life,"After intranasal and subcutaneous administrations, the elimination half life of apomorphine amounted to 31 min and 27 min, respectively.",Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588990/),min,27,68126,DB00714,Apomorphine
,23350812,Peak plasma concentration,"Peak plasma concentration was 1-3 min post-dose, and plasma level dose proportionality was observed.","Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23350812/),min,1-3,76486,DB00714,Apomorphine
,2362906,maximum effects at steady-state plasma concentrations,"In the control group, apomorphine produced bradycardia at low concentrations and tachycardia at high concentrations, while only bradycardia was registered in the malnourished group, with maximum effects at steady-state plasma concentrations of 50 ng/ml and a return to baseline at higher concentrations.",Altered pharmacokinetics and dynamics of apomorphine in the malnourished rat: modeling of the composed relationship between concentration and heart-rate response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362906/),[ng] / [ml],50,77660,DB00714,Apomorphine
,15037665,latency of onset to clinical effect,Studies have shown the latency of onset to clinical effect after s.c. injection ranged from 7.3 to 14 minutes.,Subcutaneously administered apomorphine: pharmacokinetics and metabolism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037665/),min,7.3 to 14,82736,DB00714,Apomorphine
,33650272,Bioavailability,Bioavailability of apomorphine sublingual film was ~ 18% relative to subcutaneous apomorphine.,Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33650272/),%,18,93562,DB00714,Apomorphine
,33650272,AUC0-24,"Model-predicted apomorphine exposure was similar between apomorphine sublingual film 30 mg and subcutaneous apomorphine 5 mg (median AUC0-24 , 66.7 ng•h/mL, geometric mean ratio of 0.99; 90% confidence interval [CI], 0.96-1.03) and was comparable between apomorphine sublingual film 35 mg and subcutaneous apomorphine 6 mg (median AUC0-24 , 75.4 and 80.0 ng•h/mL, respectively; geometric mean ratio of 0.94; 90% CI, 0.90-0.97) administered every 2 h for a maximum of 5 doses per day.",Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33650272/),[h·ng] / [ml],66.7,93563,DB00714,Apomorphine
,33650272,AUC0-24,"Model-predicted apomorphine exposure was similar between apomorphine sublingual film 30 mg and subcutaneous apomorphine 5 mg (median AUC0-24 , 66.7 ng•h/mL, geometric mean ratio of 0.99; 90% confidence interval [CI], 0.96-1.03) and was comparable between apomorphine sublingual film 35 mg and subcutaneous apomorphine 6 mg (median AUC0-24 , 75.4 and 80.0 ng•h/mL, respectively; geometric mean ratio of 0.94; 90% CI, 0.90-0.97) administered every 2 h for a maximum of 5 doses per day.",Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33650272/),[h·ng] / [ml],75.4,93564,DB00714,Apomorphine
,33650272,AUC0-24,"Model-predicted apomorphine exposure was similar between apomorphine sublingual film 30 mg and subcutaneous apomorphine 5 mg (median AUC0-24 , 66.7 ng•h/mL, geometric mean ratio of 0.99; 90% confidence interval [CI], 0.96-1.03) and was comparable between apomorphine sublingual film 35 mg and subcutaneous apomorphine 6 mg (median AUC0-24 , 75.4 and 80.0 ng•h/mL, respectively; geometric mean ratio of 0.94; 90% CI, 0.90-0.97) administered every 2 h for a maximum of 5 doses per day.",Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33650272/),[h·ng] / [ml],80.0,93565,DB00714,Apomorphine
,8477411,time to obtain the peak plasma concentration (tmax),The time to obtain the peak plasma concentration (tmax) obtained with the two doses were not different (0.3 mg/kg: 31.5 +/- 3.4 min; 0.6 mg/kg: 38.3 +/- 2.8 min).,Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477411/),min,31.5,93902,DB00714,Apomorphine
,8477411,time to obtain the peak plasma concentration (tmax),The time to obtain the peak plasma concentration (tmax) obtained with the two doses were not different (0.3 mg/kg: 31.5 +/- 3.4 min; 0.6 mg/kg: 38.3 +/- 2.8 min).,Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477411/),min,38.3,93903,DB00714,Apomorphine
,8477411,Cmax,"Peak plasma concentrations (Cmax) and areas under the curve (AUC) were significantly higher after 0.6 mg/kg than 0.3 mg/kg (Cmax: 0.3 mg/kg: 7.5 +/- 3.2 ng/ml; 0.6 mg/kg: 22.7 +/- 3.6 ng/ml; p < 0.01; AUC: 0.3 mg/kg: 929 +/- 109 ng/ml/min; 0.6 mg/kg; 2,277 +/- 209 ng/ml/min; p < 0.01).",Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477411/),[ng] / [ml],7.5,93904,DB00714,Apomorphine
,8477411,Cmax,"Peak plasma concentrations (Cmax) and areas under the curve (AUC) were significantly higher after 0.6 mg/kg than 0.3 mg/kg (Cmax: 0.3 mg/kg: 7.5 +/- 3.2 ng/ml; 0.6 mg/kg: 22.7 +/- 3.6 ng/ml; p < 0.01; AUC: 0.3 mg/kg: 929 +/- 109 ng/ml/min; 0.6 mg/kg; 2,277 +/- 209 ng/ml/min; p < 0.01).",Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477411/),[ng] / [ml],22.7,93905,DB00714,Apomorphine
,8477411,AUC,"Peak plasma concentrations (Cmax) and areas under the curve (AUC) were significantly higher after 0.6 mg/kg than 0.3 mg/kg (Cmax: 0.3 mg/kg: 7.5 +/- 3.2 ng/ml; 0.6 mg/kg: 22.7 +/- 3.6 ng/ml; p < 0.01; AUC: 0.3 mg/kg: 929 +/- 109 ng/ml/min; 0.6 mg/kg; 2,277 +/- 209 ng/ml/min; p < 0.01).",Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477411/),[ng] / [min·ml],929,93906,DB00714,Apomorphine
,8477411,AUC,"Peak plasma concentrations (Cmax) and areas under the curve (AUC) were significantly higher after 0.6 mg/kg than 0.3 mg/kg (Cmax: 0.3 mg/kg: 7.5 +/- 3.2 ng/ml; 0.6 mg/kg: 22.7 +/- 3.6 ng/ml; p < 0.01; AUC: 0.3 mg/kg: 929 +/- 109 ng/ml/min; 0.6 mg/kg; 2,277 +/- 209 ng/ml/min; p < 0.01).",Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477411/),[ng] / [min·ml],"2,277",93907,DB00714,Apomorphine
,2898533,Ki,"Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM).",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,1-1.3,99033,DB00714,Apomorphine
,2898533,AB50,"Compound 34, 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]hexahydro-4,7-etheno-1H- cyclobut[f]isoindole-1,3(2H)-dione, demonstrated 3 times the activity of buspirone, blocking CAR in rats with an AB50 of 13 mg/kg.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),[mg] / [kg],13,99034,DB00714,Apomorphine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,16,99035,DB00714,Apomorphine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,345,99036,DB00714,Apomorphine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,458,99037,DB00714,Apomorphine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],14138,107137,DB00714,Apomorphine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],12680,107138,DB00714,Apomorphine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],11850,107139,DB00714,Apomorphine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],9147,107140,DB00714,Apomorphine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,17.1,107141,DB00714,Apomorphine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,18.7,107142,DB00714,Apomorphine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,15.3,107143,DB00714,Apomorphine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,15.0,107144,DB00714,Apomorphine
,7531352,apparent elimination half-life,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.0,108472,DB00714,Apomorphine
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.5,108473,DB00714,Apomorphine
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,2.5,108474,DB00714,Apomorphine
,7531352,half-lives,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,3-4,108475,DB00714,Apomorphine
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,4-6,108476,DB00714,Apomorphine
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,12,108477,DB00714,Apomorphine
,22588199,t(max),A log brain/plasma concentration ratio at a t(max) of 1.48 suggests that SYA013 readily crosses the blood brain barrier (BBB).,"Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588199/),,1.48,109056,DB00714,Apomorphine
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1599,127166,DB00714,Apomorphine
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1821,127167,DB00714,Apomorphine
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1094,127168,DB00714,Apomorphine
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1129,127169,DB00714,Apomorphine
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],430,127170,DB00714,Apomorphine
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),1/[ng+ml],315,127171,DB00714,Apomorphine
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,1.9,127172,DB00714,Apomorphine
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,3.0,127173,DB00714,Apomorphine
,7192579,Sensitivity,Sensitivity was 30 ng per ml plasma.,Determination of apomorphine in plasma by selected ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192579/),[ng] / [ml·plasma],30,131787,DB00714,Apomorphine
,7885353,Maximal plasma apomorphine concentration,"Maximal plasma apomorphine concentration (25.04 ng/ml) is found 20 min after subcutaneous injection (50 micrograms/kg), and the mean area under the curve is 1,439.37 ng/ml for 120 min.",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],25.04,142039,DB00714,Apomorphine
,7885353,area under the curve,"Maximal plasma apomorphine concentration (25.04 ng/ml) is found 20 min after subcutaneous injection (50 micrograms/kg), and the mean area under the curve is 1,439.37 ng/ml for 120 min.",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],"1,439.37",142040,DB00714,Apomorphine
,7885353,maximal ventricular CSF apomorphine concentration,"In contrast to plasma values, the maximal ventricular CSF apomorphine concentration (1.08 ng/ml) is found 30 min after injection and the mean area under that curve is 7% of that of plasma (96.69 ng/ml for 120 min).",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],1.08,142041,DB00714,Apomorphine
,7885353,area under that curve,"In contrast to plasma values, the maximal ventricular CSF apomorphine concentration (1.08 ng/ml) is found 30 min after injection and the mean area under that curve is 7% of that of plasma (96.69 ng/ml for 120 min).",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),,7,142042,DB00714,Apomorphine
,7885353,area under that curve,"In contrast to plasma values, the maximal ventricular CSF apomorphine concentration (1.08 ng/ml) is found 30 min after injection and the mean area under that curve is 7% of that of plasma (96.69 ng/ml for 120 min).",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],96.69,142043,DB00714,Apomorphine
,574957,half-time,After intracerebroventricular injections apomorphine was eliminated according to equations for the one-compartment open model: the elimination of the drug from the cerebrospinal fluid to circulation was rapid (half-time approx. 9 min).,Behavioral effects and cerebral pharmacokinetics of apomorphine in the rat: dependence upon the route of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/574957/),min,9,142365,DB00714,Apomorphine
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],19.9,143867,DB00714,Apomorphine
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],6.2,143868,DB00714,Apomorphine
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],22.5,143869,DB00714,Apomorphine
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],21.0,143870,DB00714,Apomorphine
,9453072,maximum concentrations,The maximum concentrations that were attained were related to the applied current density: 1.3 +/- 0.6 ng.,Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453072/),ng,1.3,146499,DB00714,Apomorphine
<,20740670,oral bioavailability,"Apomorphine, a dopamine receptor agonist for treating Parkinson's disease, has very poor oral bioavailability (<2%) due to the first-pass effect.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),%,2,151760,DB00714,Apomorphine
,20740670,diameters,"Mean diameters of the GMS and PMS systems were 155 and 63 nm, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),nm,155,151761,DB00714,Apomorphine
,20740670,diameters,"Mean diameters of the GMS and PMS systems were 155 and 63 nm, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),nm,63,151762,DB00714,Apomorphine
,20740670,total number of rotations,"The total number of rotations increased from 20 to 94 and from 20 to 115 when the drug was administered from SLNs containing GMS and PMS, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),,20 to 94,151763,DB00714,Apomorphine
,20740670,total number of rotations,"The total number of rotations increased from 20 to 94 and from 20 to 115 when the drug was administered from SLNs containing GMS and PMS, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),,20 to 115,151764,DB00714,Apomorphine
,32795778,Extraction recoveries,"Extraction recoveries were found to be 73.4 % (apomorphine), 81.1 % (apomorphine sulfate), and 58.6 % (norapomorphine).",LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795778/),%,73.4,159847,DB00714,Apomorphine
,32795778,Extraction recoveries,"Extraction recoveries were found to be 73.4 % (apomorphine), 81.1 % (apomorphine sulfate), and 58.6 % (norapomorphine).",LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795778/),%,81.1,159848,DB00714,Apomorphine
,32795778,Extraction recoveries,"Extraction recoveries were found to be 73.4 % (apomorphine), 81.1 % (apomorphine sulfate), and 58.6 % (norapomorphine).",LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795778/),%,58.6,159849,DB00714,Apomorphine
,32795778,stabilities,"Established long-term plasma frozen storage stabilities were 504 days at -20 °C and276 days at -60 °C, respectively.",LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795778/),d,504,159850,DB00714,Apomorphine
,32795778,stabilities,"Established long-term plasma frozen storage stabilities were 504 days at -20 °C and276 days at -60 °C, respectively.",LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32795778/),d,276,159851,DB00714,Apomorphine
,7820259,chemical half-life,The chemical half-life is only 39 min.,Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820259/),min,39,163903,DB00714,Apomorphine
,7820259,recovery,Biological samples are extracted with diethyl ether (recovery 96.5%) and analysed using HPLC with coulometric detection (oxidation potential 0.25 V).,Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820259/),%,96.5,163904,DB00714,Apomorphine
,7820259,flow-rate,The flow-rate was 1.8 ml/min.,Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820259/),[ml] / [min],1.8,163905,DB00714,Apomorphine
,16778727,flow rate,"The elution was achieved isocratically with a mobile phase of 2 mM NH4COOH buffer pH 3.8/acetonitrile (50/50, vol/vol) at a flow rate of 200 microL per minute.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),[μl] / [min],200,170729,DB00714,Apomorphine
,16778727,Retention times,"Retention times were 2.03 and 2.11 minutes for boldine and apomorphine, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),min,2.03,170730,DB00714,Apomorphine
,16778727,Retention times,"Retention times were 2.03 and 2.11 minutes for boldine and apomorphine, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),min,2.11,170731,DB00714,Apomorphine
,16778727,limits of detection,"The limits of detection and quantification were 0.010 ng/mL and 0.025 ng/mL, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),[ng] / [ml],0.010,170732,DB00714,Apomorphine
,16778727,limits of detection,"The limits of detection and quantification were 0.010 ng/mL and 0.025 ng/mL, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),[ng] / [ml],0.025,170733,DB00714,Apomorphine
,7197717,absolute bioavailability,The absolute bioavailability of apomorphine was 4%.,Apomorphine: bioavailability and effect on stereotyped cage climbing in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197717/),%,4,173607,DB00714,Apomorphine
,7197717,absolute bioavailability,Analysis of time-course data obtained from the cage-climbing experiments indicated an absolute bioavailability of 16% for apomorphine.,Apomorphine: bioavailability and effect on stereotyped cage climbing in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197717/),%,16,173608,DB00714,Apomorphine
,7608665,tmax,The tmax ranged from five to 45 minutes (16 patients).,"Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608665/),min,five to 45,182444,DB00714,Apomorphine
,9449564,flow-rate,At a flow-rate of 0.9 ml min(-1) the total run time is ca. 15 min.,"Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),[ml] / [min],0.9,190569,DB00714,Apomorphine
,9449564,total run time,At a flow-rate of 0.9 ml min(-1) the total run time is ca. 15 min.,"Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),min,15,190570,DB00714,Apomorphine
,9449564,detection limits,"The detection limits are 0.3 and 0.6 ng ml(-1) for R- and S- apomorphine, respectively (signal-to-noise ratio 3).","Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),[ng] / [ml],0.3,190571,DB00714,Apomorphine
,9449564,detection limits,"The detection limits are 0.3 and 0.6 ng ml(-1) for R- and S- apomorphine, respectively (signal-to-noise ratio 3).","Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),[ng] / [ml],0.6,190572,DB00714,Apomorphine
,9449564,signal-to-noise ratio,"The detection limits are 0.3 and 0.6 ng ml(-1) for R- and S- apomorphine, respectively (signal-to-noise ratio 3).","Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),,3,190573,DB00714,Apomorphine
,9449564,flow-rate,At a flow-rate of 0.8 ml min(-1) the total run time is ca. 14 min.,"Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),[ml] / [min],0.8,190574,DB00714,Apomorphine
,9449564,total run time,At a flow-rate of 0.8 ml min(-1) the total run time is ca. 14 min.,"Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),min,14,190575,DB00714,Apomorphine
,9449564,detection limits,The detection limits of this assay are 1.0 ng ml(-1) for apomorphine and 2.5 ng ml(-1) for both apocodeine and isoapocodeine (signal-to-noise ratio 3).,"Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),[ng] / [ml],1.0,190576,DB00714,Apomorphine
,9449564,detection limits,The detection limits of this assay are 1.0 ng ml(-1) for apomorphine and 2.5 ng ml(-1) for both apocodeine and isoapocodeine (signal-to-noise ratio 3).,"Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),[ng] / [ml],2.5,190577,DB00714,Apomorphine
,9449564,signal-to-noise ratio,The detection limits of this assay are 1.0 ng ml(-1) for apomorphine and 2.5 ng ml(-1) for both apocodeine and isoapocodeine (signal-to-noise ratio 3).,"Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449564/),,3,190578,DB00714,Apomorphine
,1773424,latency,"In acute studies, all 10 patients switched ""on"" after a mean latency of 25 min with a mean duration of motor benefit of 118 min.",Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773424/),min,25,190640,DB00714,Apomorphine
,1773424,Cmax,"The pattern of clinical response followed closely the plasma profile of apomorphine with a mean Cmax of 76 pmol/ml (50-106 pmol/ml) and a mean Tmax of 60 min (45-80 min), with moderate interpatient variability in bioavailability.",Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773424/),[pM] / [ml],76,190641,DB00714,Apomorphine
,1773424,Tmax,"The pattern of clinical response followed closely the plasma profile of apomorphine with a mean Cmax of 76 pmol/ml (50-106 pmol/ml) and a mean Tmax of 60 min (45-80 min), with moderate interpatient variability in bioavailability.",Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773424/),min,60,190642,DB00714,Apomorphine
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],246,194495,DB00714,Apomorphine
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],180,194496,DB00714,Apomorphine
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],205,194497,DB00714,Apomorphine
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],0.98,194498,DB00714,Apomorphine
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],1.70,194499,DB00714,Apomorphine
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],3.67,194500,DB00714,Apomorphine
,8149359,time lag,The time lag between the highest level of apomorphine in plasma and CSF was 20 min for patient A and 10 min for patient B.,Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149359/),min,20,214519,DB00714,Apomorphine
,8149359,time lag,The time lag between the highest level of apomorphine in plasma and CSF was 20 min for patient A and 10 min for patient B.,Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149359/),min,10,214520,DB00714,Apomorphine
,9316694,time to peak plasma concentration,The time to peak plasma concentration (29.4 +/- 7.8 min) was close than after the subcutaneous route (25.8 +/- 4.9 min).,Comparison between percutaneous and subcutaneous routes of administration of apomorphine in rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316694/),min,29.4,215984,DB00714,Apomorphine
,9316694,time to peak plasma concentration,The time to peak plasma concentration (29.4 +/- 7.8 min) was close than after the subcutaneous route (25.8 +/- 4.9 min).,Comparison between percutaneous and subcutaneous routes of administration of apomorphine in rabbit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316694/),min,25.8,215985,DB00714,Apomorphine
,9316694,absorption,"The absorption of apomorphine was of 90% at minute 68 and minute 321 min after the subcutaneous and the percutaneous route, respectively.",Comparison between percutaneous and subcutaneous routes of administration of apomorphine in rabbit. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316694/),%,90,215986,DB00714,Apomorphine
,16715476,limit of detection (LOD),The limit of detection (LOD) obtained was 0.03 ng/mL.,Development of a sensitive and rapid liquid chromatography/tandem mass spectrometry method for the determination of apomorphine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715476/),[ng] / [ml],0.03,222866,DB00714,Apomorphine
,7927855,Vslope,"We found a median Vslope of 1.7408 +/- 0.8461 (S.D.) 1/kg, and a mean Kel of 1.5341 +/- 0.3748 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),[1] / [kg],1.7408,224826,DB00714,Apomorphine
,7927855,Kel,"We found a median Vslope of 1.7408 +/- 0.8461 (S.D.) 1/kg, and a mean Kel of 1.5341 +/- 0.3748 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),1/[h],1.5341,224827,DB00714,Apomorphine
,7927855,Ka,"The absorption after intranasal administration was extremely rapid: Ka = 20.5 +/- 1.96 h-1, comparable with that found with subcutaneous absorption: Ka = 23.04 +/- 2.20 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),1/[h],20.5,224828,DB00714,Apomorphine
,7927855,Ka,"The absorption after intranasal administration was extremely rapid: Ka = 20.5 +/- 1.96 h-1, comparable with that found with subcutaneous absorption: Ka = 23.04 +/- 2.20 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),1/[h],23.04,224829,DB00714,Apomorphine
,33991326,time to maximum plasma concentration (tmax),Median time to maximum plasma concentration (tmax) of apomorphine was 0.63-0.75 h for APL and 0.25-0.38 h for SC-APO and SC-APO-GO.,"Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and ""OFF"" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991326/),h,0.63-0.75,237979,DB00714,Apomorphine
,33991326,time to maximum plasma concentration (tmax),Median time to maximum plasma concentration (tmax) of apomorphine was 0.63-0.75 h for APL and 0.25-0.38 h for SC-APO and SC-APO-GO.,"Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and ""OFF"" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991326/),h,0.25-0.38,237980,DB00714,Apomorphine
,33991326,maximum plasma concentration (Cmax),Geometric mean maximum plasma concentration (Cmax) of apomorphine was 4.31-11.2 ng/ml across APL doses and was generally lower compared with SC apomorphine formulations within dose groups.,"Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and ""OFF"" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991326/),[ng] / [ml],4.31-11.2,237981,DB00714,Apomorphine
,33991326,Relative bioavailability,"Relative bioavailability of APL was ~ 17% of SC apomorphine by AUC∞; SC-APO and SC-APO-GO had similar bioavailability (98% and 83% by AUC∞ and Cmax, respectively).","Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and ""OFF"" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991326/),%,17,237982,DB00714,Apomorphine
,33991326,bioavailability,"Relative bioavailability of APL was ~ 17% of SC apomorphine by AUC∞; SC-APO and SC-APO-GO had similar bioavailability (98% and 83% by AUC∞ and Cmax, respectively).","Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and ""OFF"" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991326/),%,98,237983,DB00714,Apomorphine
,33991326,bioavailability,"Relative bioavailability of APL was ~ 17% of SC apomorphine by AUC∞; SC-APO and SC-APO-GO had similar bioavailability (98% and 83% by AUC∞ and Cmax, respectively).","Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and ""OFF"" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991326/),%,83,237984,DB00714,Apomorphine
,26295148,zeta potential,OLA-LNC were successfully developed with a particle size of 142 ± 4 nm and a zeta potential of -19.6 ± 0.6 mV.,Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26295148/),mv,-19.6,242212,DB00714,Apomorphine
,26295148,relative bioavailability,"Higher olanzapine concentrations and AUC(0-12 h) were found in plasma and tissues evaluated after the administration of OLA-LNC compared to the drug in the free form, resulting in a relative bioavailability of 226.7% in the plasma.",Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26295148/),%,226.7,242213,DB00714,Apomorphine
,2774511,distribution half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,5,247981,DB00714,Apomorphine
,2774511,elimination half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,33,247982,DB00714,Apomorphine
,8748619,elimination half life,"Apomorphine is lipophilic; it has a large volume of distribution and is rapidly cleared from plasma, with an elimination half life of 33 minutes.",Pharmacokinetics of apomorphine in Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748619/),min,33,255582,DB00714,Apomorphine
,33333142,bioavailability,"Current in vivo study in pigs showed: (1) steady plateau levels of apomorphine in plasma were obtained 30 min following administration and remained constant for 8 h until a delivery device was removed, (2) bioavailability of apomorphine was 55%-80% as opposed to <2% peroral and (3) simulation of the pharmacokinetic profile obtained in pigs predicted therapeutically relevant levels of apomorphine in human.","Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333142/),%,55,265212,DB00714,Apomorphine
<,33333142,bioavailability,"Current in vivo study in pigs showed: (1) steady plateau levels of apomorphine in plasma were obtained 30 min following administration and remained constant for 8 h until a delivery device was removed, (2) bioavailability of apomorphine was 55%-80% as opposed to <2% peroral and (3) simulation of the pharmacokinetic profile obtained in pigs predicted therapeutically relevant levels of apomorphine in human.","Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333142/),%·peroral,2,265213,DB00714,Apomorphine
,8370571,Tmax,"After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min).",Pharmacokinetics of apomorphine in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8370571/),min,16,266247,DB00714,Apomorphine
,8370571,plasma half-life,"After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min).",Pharmacokinetics of apomorphine in parkinsonian patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8370571/),min,69.7,266248,DB00714,Apomorphine
,15588905,bioavailability,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),%,10.6,267590,DB00714,Apomorphine
,15588905,bioavailability,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),%,13.2,267591,DB00714,Apomorphine
,15588905,steady state input rate,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),[nM] / [cm2·h],75.3,267592,DB00714,Apomorphine
,15588905,steady state input rate,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),[nM] / [cm2·h],98.3,267593,DB00714,Apomorphine
